Sensus Healthcare’s SRT-100 has received clearance from the U.S. Food and Drug Administration to treat keloid scars caused by surgery or injury. The superficial radiotherapy (SRT) device was previously approved for the treatment of non-melanoma skin cancers in hospitals and private practice settings. Its SharpBeam technology targets only the lesion that is being treated, while the surrounding and underlying healthy tissue is spared.
"Painful and potentially disfiguring keloid scars are very difficult to effectively treat by surgery or other means due to recurrence rates as high as 45% to 100%. Studies show that the use of adjunctive radiation therapy can dramatically reduce the rate of recurrences," said Mark S. Nestor , MD, PhD of the Center for Cosmetic Enhancement in Aventura, Florida.
"The SRT-100 technology continues to demonstrate its potential as we expand our indications into other areas of treatment. This important indication can be applied to every surgical procedure for those patients susceptible to forming keloids," said Joe Sardano , President/CEO, Sensus Healthcare.

Image copyright iStockphoto.com